Verified Insights
Precision-driven research you can trust. We uphold rigorous data validation processes to ensure every report is reliable and based on credible sources.
+91 9425150513 (Asia) support@24lifesciences.com
+91 9425150513 (Asia) support@24lifesciences.com
MARKET INSIGHTS
The global Size Exclusion Chromatography (SEC) HPLC Column market was valued at USD 477 million in 2024 and is projected to reach USD 880 million by 2031, exhibiting a CAGR of 9.2% during the forecast period.
Size exclusion chromatography (SEC) is a major mode of HPLC that employs porous particles in the column to separate molecules by virtue of their size in solution. SEC is generally used to separate biological molecules, to determine molecular weight distributions of proteins and peptides, as well as to separate a wide range of water-soluble polymers used across various industries.
The market growth is primarily driven by increasing demand for characterization and quality control of biologics, including monoclonal antibodies, gene therapies, and other complex therapeutic proteins. The rising adoption of biologics in treating cancer, autoimmune diseases, and rare genetic disorders has significantly increased the need for precise analytical techniques like SEC. Additionally, advancements in column technology enabling higher resolution and faster separations are making SEC more accessible and cost-effective for a broader range of laboratories.
However, the market faces challenges including the high cost of high-performance columns, particularly for UHPLC systems, which can be prohibitive for smaller laboratories. Additionally, SEC has inherent limitations in resolving very similar molecular sizes, sometimes requiring complementary techniques. Column fouling and maintenance requirements also add to operational costs, especially when analyzing complex or viscous samples.
North America holds the largest market share at approximately 33%, followed by Europe and Asia-Pacific. The 4.6-7.8mm internal diameter segment dominates with over 70% market share due to its optimal balance between resolution capacity and sample loading capacity. Key players include Agilent Technologies, Waters Corporation, Shimadzu, Tosoh Corporation, Thermo Fisher Scientific, and Danaher, among others.
Increasing Demand for Biopharmaceuticals
The global biopharmaceutical market continues to expand rapidly, with monoclonal antibodies, vaccines, and recombinant proteins requiring precise molecular weight analysis that SEC-HPLC columns excel at providing. This drives demand for high-performance separation technologies.
Rising Quality Control Requirements
Pharmaceutical regulatory agencies worldwide are implementing stricter guidelines for polymer characterization and impurity profiling. SEC-HPLC columns provide the necessary resolution for meeting these requirements, particularly in biosimilar characterization and biosimilarity studies.
The global biopharmaceutical market is projected to reach $856 billion by 2028, driving demand for advanced analytical techniques like SEC-HPLC
Regulatory requirements for biotherapeutic characterization continue to evolve, with emphasis on higher-order structure analysis that SEC techniques are particularly well-suited to address.
MARKET CHALLENGES
High Instrumentation Costs
The initial investment for a complete SEC-HPLC system, including columns, detectors, and pumps, can exceed $50,000, creating barriers for small research facilities and academic laboratories. This is particularly challenging for institutions in developing regions.
Other Challenges
Column Fouling and Maintenance
SEC columns require regular maintenance and careful handling to prevent fouling from biological samples. The need for specialized cleaning protocols and potential for column degradation add to operational challenges.
Alternative Technologies
Alternative separation techniques such as field-flow fractionation (FFF) and advanced mass spectrometry methods compete with SEC-HPLC in certain applications. While SEC provides excellent molecular weight distribution data, other techniques may offer complementary information that can reduce reliance on any single methodology.
Emerging Markets Expansion
As biopharmaceutical production expands into emerging economies, the demand for quality control instrumentation creates new markets. Countries like Brazil, India, and China are increasing their biologics production capabilities, requiring advanced analytical equipment including SEC-HPLC systems.
Technological advancements in column chemistry are enabling higher resolution separations with shorter analysis times. New stationary phases with improved pore structures and surface chemistries are allowing better separation of complex biotherapeutic mixtures, opening new application areas in personalized medicine and complex generics.
Segment Analysis:| Segment Category | Sub-Segments | Key Insights |
| By Type |
|
ID 4.6-7.8mm columns represent the dominant segment due to their optimal balance between resolution, pressure tolerance, and sample loading capacity, making them ideal for a wide array of analytical applications from protein characterization to polymer analysis. Their versatility and compatibility with standard HPLC systems solidify their position as the preferred choice for most laboratories. Smaller internal diameter columns are gaining traction for applications requiring minimal solvent consumption and high sensitivity, while larger diameters remain niche products primarily used for preparative-scale separations. |
| By Application |
|
Pharmaceutical and Biotech Companies constitute the leading application segment, driven by the critical need for SEC in the development and quality control of biologic drugs. These columns are indispensable for characterizing complex molecules like monoclonal antibodies and therapeutic proteins, ensuring product purity, stability, and regulatory compliance. Academic and research institutions represent a significant user base focused on fundamental research in proteomics and polymer science. The 'Others' category is experiencing steady growth, with Contract Research Organizations leveraging SEC for client projects and industries like food and beverage adopting the technology for quality assurance of natural polymers and additives. |
| By End User |
|
Large Enterprises, particularly major pharmaceutical and biotechnology corporations, are the foremost end-user segment. Their dominance is attributed to substantial R&D budgets, high-volume production needs for quality control, and the financial capacity to invest in advanced chromatographic systems and consumables. Small and medium-sized enterprises represent a growing segment, often specializing in niche biotech applications, though they face challenges related to the initial cost of high-performance columns. Government and public research laboratories form a stable user base, utilizing SEC for a diverse range of publicly funded scientific investigations and standard-setting activities. |
| By Separation Mechanism |
|
Analytical SEC is the leading mechanism, forming the core of the market as it is used for routine analysis, quality control, and molecular weight determination across all application areas. The demand for precise characterization of biomolecules in drug development sustains this segment's prominence. Preparative SEC is crucial for purifying and isolating specific fractions of a sample for further analysis or use, which is vital in downstream bioprocessing. High-Resolution SEC, utilizing UHPLC technology, is a rapidly advancing segment valued for its superior speed and separation power, though its adoption is tempered by higher system and column costs. |
| By Stationary Phase |
|
Silica-based Columns are the most widely used stationary phase due to their excellent mechanical strength, high efficiency, and well-established manufacturing processes, making them suitable for a broad pH range and high-pressure applications common in HPLC. Polymer-based columns offer superior biocompatibility and resistance to extreme pH conditions, which is critical for certain biological separations where silica may cause undesirable interactions. Hybrid technology columns are an innovative segment gaining acceptance; they combine the robustness of silica with enhanced pH stability, offering a versatile solution that is expanding the operational boundaries of SEC methodologies for challenging samples. |
A Concentrated Market Led by Global Life Science Giants
The global Size Exclusion Chromatography (SEC) HPLC Column market is characterized by the dominance of a select group of major multinational corporations that provide comprehensive analytical instrument solutions. Agilent Technologies and Waters Corporation are the clear market leaders, collectively holding approximately 26% of the global market share. These players benefit from their extensive product portfolios, strong brand recognition, global distribution networks, and deep-rooted relationships with major pharmaceutical and biotechnology companies. The market structure is moderately concentrated, with competition primarily revolving around product performance, resolution, reproducibility, and the provision of robust technical support and services. These leading companies invest heavily in research and development to introduce advanced columns with improved packing materials, such as silica and polymeric beads, offering higher efficiency and longer column life to meet the stringent demands of biopharmaceutical quality control and research applications.
Beyond the top-tier players, the market includes several other significant companies that compete by specializing in specific niches or by offering cost-effective alternatives. Companies like Tosoh Corporation and Bio-Rad Laboratories are particularly strong in the field of bio-separations, offering specialized SEC columns for protein analysis. Meanwhile, Shimadzu and Thermo Fisher Scientific leverage their broad instrument platforms to provide integrated HPLC and UHPLC solutions. Specialized players such as Malvern Instruments (now part of Spectris) focus on characterization, while Sepax Technologies and Polymer Standards Service cater to specific polymer analysis and custom separation needs. This diverse competitive environment ensures a wide range of product choices for different applications, from academic research to large-scale industrial bioprocessing.
List of Key Size Exclusion Chromatography (SEC) HPLC Column Companies ProfiledAgilent Technologies
Shimadzu Corporation
Tosoh Corporation
Danaher Corporation
Merck KGaA
Malvern Panalytical (Spectris)
Polymer Standards Service GmbH
YMC Co., Ltd.
Hitachi High-Tech Corporation
Knauer Wissenschaftliche Gerte GmbH
PAC L.P. (A Roper Technologies Company)
The global Size Exclusion Chromatography (SEC) HPLC Column market is on a strong growth trajectory, with its value projected to expand from $477 million in 2024 to approximately $880 million by 2031, representing a compound annual growth rate (CAGR) of 9.2%. This significant growth is primarily fueled by the escalating demand from the biopharmaceutical sector. SEC columns are indispensable for characterizing large biomolecules, including proteins, monoclonal antibodies, and gene therapies. The need to ensure the purity, safety, and efficacy of these complex biologic drugs during development and quality control processes is a major market driver, making high-performance SEC analysis a non-negotiable standard in the industry.
Other TrendsTechnological Advancements in Column Performance
Manufacturers are continuously innovating to enhance SEC column technology. Key developments include the introduction of advanced packing materials that offer higher resolution and faster separation times. This is particularly important for ultra-high-performance liquid chromatography (UHPLC) systems, which demand columns capable of withstanding high pressures while providing precise molecular weight distribution data. These improvements are increasing the adoption of SEC columns in both research and manufacturing environments, enabling more efficient and accurate analyses.
North America currently dominates the SEC HPLC column market, holding about 33% of the global share, largely due to its robust biopharmaceutical and research infrastructure. Europe and the Asia-Pacific region follow as significant markets. The competitive landscape is characterized by key players such as Agilent Technologies, Waters Corporation, and Thermo Fisher Scientific, with the top two companies collectively holding approximately 26% of the market. In terms of product segmentation, columns with an internal diameter (ID) between 4.6mm and 7.8mm constitute the largest segment, accounting for over 70% of sales, as they offer a balance between resolution and sample loading capacity suitable for a wide range of applications.
Regional Analysis: Size Exclusion Chromatography (SEC) HPLC Column MarketEurope
Europe represents a mature and significant market for SEC-HPLC columns, characterized by a strong academic research base and a thriving pharmaceutical industry, particularly in countries like Germany, the UK, and Switzerland. The market is driven by significant investments in biopharmaceutical research and a focus on biosimilar development. The region's emphasis on stringent regulatory compliance, aligned with the European Medicines Agency (EMA) guidelines, ensures a steady demand for high-quality analytical columns for drug characterization. Collaborative research projects across European Union member states also foster innovation and standardization in separation sciences. The presence of several leading chromatography instrumentation manufacturers contributes to a competitive landscape, offering a diverse portfolio of SEC columns tailored for various applications in protein analysis and polymer characterization.
Asia-Pacific
The Asia-Pacific region is the fastest-growing market for SEC-HPLC columns, fueled by rapidly expanding pharmaceutical and biotechnology sectors in China, India, Japan, and South Korea. Increasing government and private investments in life sciences research, coupled with growing outsourcing of analytical testing to contract research organizations (CROs), are key growth drivers. The region benefits from cost-effective manufacturing capabilities, leading to the presence of both international and local column suppliers. While the market is expanding quickly, it is also characterized by a growing focus on improving research quality and adherence to international regulatory standards. The demand is increasingly shifting from basic research applications to more complex analyses required for biologics development, indicating a market that is maturing rapidly.
South America
The SEC-HPLC column market in South America is emerging, with growth primarily concentrated in Brazil and Argentina. The market is supported by a developing biotechnology industry and increasing government initiatives to bolster local pharmaceutical production. However, growth is tempered by economic volatility and relatively lower R&D expenditure compared to more developed regions. The demand is primarily from academic research institutions and a handful of large pharmaceutical companies, focusing on basic protein analysis and quality control. Market penetration by international suppliers is increasing, but the region still relies heavily on imports for high-performance columns, with price sensitivity being a significant factor influencing purchasing decisions.
Middle East & Africa
This region represents a smaller but developing market for SEC-HPLC columns. Growth is nascent and largely driven by increasing investment in healthcare infrastructure and academic research, particularly in Gulf Cooperation Council (GCC) countries like Saudi Arabia and the UAE. The market is characterized by a focus on applications in food and environmental analysis alongside foundational life sciences research. The presence of the market is currently limited, with demand stemming mainly from a few major universities and government research centers. The reliance on international suppliers is almost total, and market growth is closely tied to broader economic development and the gradual expansion of local biotech capabilities.
This market research report offers a holistic overview of global and regional markets for the forecast period 20252032. It presents accurate and actionable insights based on a blend of primary and secondary research.
Market Overview
Global and regional market size (historical & forecast)
Growth trends and value/volume projections
<>Segmentation Analysis
By product type or category
By application or usage area
By end-user industry
By distribution channel (if applicable)
Regional Insights
North America, Europe, Asia-Pacific, Latin America, Middle East & Africa
Country-level data for key markets
Competitive Landscape
Company profiles and market share analysis
Key strategies: M&A, partnerships, expansions
Product portfolio and pricing strategies
Technology & Innovation
Emerging technologies and R&D trends
Automation, digitalization, sustainability initiatives
Impact of AI, IoT, or other disruptors (where applicable)
Market Dynamics
Key drivers supporting market growth
Restraints and potential risk factors
pply chain trends and challenges
Opportunities & Recommendations
High-growth segments
Investment hotspots
Strategic suggestions for stakeholders
Stakeholder Insights
This report is designed to support strategic decision-making for a wide range of stakeholders, including:
Pharmaceutical and biotech companies
Medical device and diagnostics manufacturers
Healthcare providers and hospital systems
Contract research and manufacturing organizations
Investors, consultants, and policy makers
-> Global Size Exclusion Chromatography (SEC) HPLC Column market was valued at USD 477 million in 2024 and is expected to reach USD 880 million by 2031.
-> Key players include Agilent Technologies, Waters Corporation, Shimadzu, Tosoh Corporation, Thermo Fisher Scientific, and Danaher, among others.
-> Key growth drivers include increasing demand for biologic drug characterization, rising adoption of biopharmaceuticals, and advancements in column technology.
-> North America holds the largest market share at approximately 33%, followed by Europe and Asia-Pacific.
-> Major challenges include high cost of columns, limitations in resolving closely related biomolecules, and column maintenance requirements.
“The data provided by 24LifeScience was clear, well-organized, and useful for internal strategy planning. It helped us understand the competitive landscape more effectively.”
“We used one of their market overview reports for early-stage feasibility work. It gave us a helpful snapshot of current trends and key players in our therapeutic area.”
“I appreciated the team’s responsiveness and willingness to adjust the scope based on our feedback. The final report was aligned with our expectations and timelines.”
“Their custom report on clinical trial trends was a helpful reference as we explored new indications."
“As someone working on early product planning, I found their therapeutic area briefs quite useful. The information was presented in a way that made it easy to extract key takeaways.”
“We didn’t need anything overly complex—just solid, dependable data. 24LifeScience delivered exactly that, without unnecessary fluff.”
“Their reports gave us a good foundation to start our own market assessment. While we supplemented it with other data, this was a great starting point.”
“I’ve used a few of their reports for academic and grant writing purposes. They’re generally well-cited and reliable for understanding market scope.”
At 24LifeScience, we combine domain expertise with dependable research delivery. What truly differentiates us isn't just what we do — it's how we do it. Our clients trust us because we offer consistency, security, value, and most importantly, insight that drives action.
Precision-driven research you can trust. We uphold rigorous data validation processes to ensure every report is reliable and based on credible sources.
We uphold rigorous data validation processes to ensure every report is reliable, up-to-date, and based on credible sources.
24LifeScience powers research for top firms in 20+ nations.Chosen by leading life sciences companies worldwide.
We offer competitive pricing models that align with your project scope — no hidden charges, no lock-in. Tailored pricing for every scale and need.
8–10+ years of life sciences expertise turned into strategic insights.We don’t just summarize data we contextualize it.
Whether it's a ready-made report or a custom project, we deliver within the promised timeline With real-time updates